Free Trial
Your Portfolio Deserves Better! MarketBeat All Access for Just $149
Upgrade Now
Claim MarketBeat All Access Sale Promotion

AtriCure (ATRC) Financials

AtriCure logo
$29.00 +0.20 (+0.69%)
Closing price 04:00 PM Eastern
Extended Trading
$28.99 -0.01 (-0.03%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for AtriCure

Annual Income Statements for AtriCure

This table shows AtriCure's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -27 -33 -27 -21 -35 -48 50 -46 -30 -45 -11
Consolidated Net Income / (Loss)		 -27 -33 -27 -21 -35 -48 50 -46 -30 -45 -11
Net Income / (Loss) Continuing Operations		 -27 -33 -27 -21 -35 -48 50 -46 -30 -45 -11
Total Pre-Tax Income 		-27 -33 -27 -21 -35 -48 50 -46 -30 -44 -10
Total Operating Income		 -27 -31 -25 -17 -33 -44 55 -43 -27 -40 -9.45
Total Gross Profit		 93 111 126 147 170 149 206 246 300 348 401
Total Revenue		 130 155 175 202 231 207 274 330 399 465 535
Operating Revenue		 130 155 175 202 231 207 274 330 399 465 535
Total Cost of Revenue		 37 44 49 55 60 57 68 84 99 118 134
Operating Cost of Revenue		 37 44 49 55 60 57 68 84 99 118 134
Total Operating Expenses		 120 142 151 164 203 194 151 289 327 388 410
Selling, General & Admin Expense		 94 106 117 130 167 151 205 231 253 291 311
Research & Development Expense		 26 36 34 35 41 43 49 57 74 96 99
Total Other Income / (Expense), net		 -0.46 -2.16 -1.90 -3.78 -1.87 -3.81 -4.82 -3.53 -3.16 -3.66 -0.72
Interest Expense		 0.29 1.80 2.26 4.61 4.11 4.89 4.92 4.99 6.93 7.77 5.88
Interest & Investment Income		 0.19 0.23 0.23 1.01 2.40 1.10 0.47 1.99 3.79 4.43 4.48
Other Income / (Expense), net		 -0.35 -0.59 0.14 -0.18 -0.16 -0.02 -0.37 -0.54 -0.03 -0.33 0.68
Income Tax Expense		 0.04 0.04 0.01 0.23 0.20 0.11 0.19 0.27 0.59 1.02 1.29
Basic Earnings per Share		 ($0.97) ($1.05) ($0.83) ($0.62) ($0.94) ($1.14) $1.11 ($1.02) ($0.66) ($0.95) ($0.24)
Weighted Average Basic Shares Outstanding		 28.06M 31.61M 32.39M 34.09M 37.59M 42.13M 45.07M 45.74M 46.31M 46.97M 47.75M
Diluted Earnings per Share		 ($0.97) ($1.05) ($0.83) ($0.62) ($0.94) ($1.14) $1.09 ($1.02) ($0.66) ($0.95) ($0.24)
Weighted Average Diluted Shares Outstanding		 28.06M 31.61M 32.39M 34.09M 37.59M 42.13M 46.04M 45.74M 46.31M 46.97M 47.75M
Weighted Average Basic & Diluted Shares Outstanding		 28.06M 31.61M 32.39M 34.09M 37.59M 42.13M 46.03M 93.14M 95.18M 48.88M 49.81M

Quarterly Income Statements for AtriCure

This table shows AtriCure's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -9.06 -9.79 -13 -8.01 -7.85 -16 -6.75 -6.19 -0.27 1.76 0.11
Consolidated Net Income / (Loss)		 -9.06 -9.79 -13 -8.01 -7.85 -16 -6.75 -6.19 -0.27 1.76 0.11
Net Income / (Loss) Continuing Operations		 -9.06 -9.79 -13 -8.01 -7.85 -16 -6.75 -6.19 -0.27 1.76 0.11
Total Pre-Tax Income 		-9.01 -9.42 -13 -7.76 -7.53 -15 -6.51 -5.93 -0.09 2.36 0.39
Total Operating Income		 -8.09 -8.67 -11 -7.17 -7.41 -15 -5.95 -6.19 0.21 2.49 0.53
Total Gross Profit		 74 80 81 87 87 93 93 101 101 105 109
Total Revenue		 98 107 109 116 116 124 124 136 134 141 141
Operating Revenue		 98 107 109 116 116 124 124 136 134 141 141
Total Cost of Revenue		 24 27 28 29 29 32 31 35 33 35 32
Operating Cost of Revenue		 24 27 28 29 29 32 31 35 33 35 32
Total Operating Expenses		 82 88 92 94 94 107 99 108 101 103 109
Selling, General & Admin Expense		 62 68 72 74 73 72 76 78 78 78 85
Research & Development Expense		 20 21 20 20 21 35 23 29 23 25 24
Total Other Income / (Expense), net		 -0.92 -0.75 -2.17 -0.59 -0.13 -0.78 -0.55 0.26 -0.29 -0.13 -0.13
Interest Expense		 1.77 1.80 3.04 1.61 1.67 1.45 1.42 1.49 1.47 1.50 1.34
Interest & Investment Income		 0.92 1.04 0.95 1.00 1.28 1.20 1.04 0.94 1.17 1.33 1.25
Other Income / (Expense), net		 -0.06 0.01 -0.08 0.03 0.26 -0.53 -0.18 0.81 0.01 0.04 -0.04
Income Tax Expense		 0.05 0.37 0.18 0.25 0.32 0.27 0.24 0.26 0.18 0.60 0.29
Basic Earnings per Share		 ($0.20) ($0.21) ($0.28) ($0.17) ($0.17) ($0.33) ($0.14) ($0.13) ($0.01) $0.04 $0.00
Weighted Average Basic Shares Outstanding		 46.41M 46.31M 46.72M 46.91M 47.11M 46.97M 47.39M 47.72M 47.92M 47.75M 48.33M
Diluted Earnings per Share		 ($0.20) ($0.21) ($0.28) ($0.17) ($0.17) ($0.33) ($0.14) ($0.13) ($0.01) $0.04 $0.00
Weighted Average Diluted Shares Outstanding		 46.41M 46.31M 46.72M 46.91M 47.11M 46.97M 47.39M 47.72M 47.92M 47.75M 49.05M
Weighted Average Basic & Diluted Shares Outstanding		 47.40M 95.18M 48.38M 48.70M 48.75M 48.88M 49.50M 49.70M 49.72M 49.81M 50.64M

Annual Cash Flow Statements for AtriCure

This table details how cash moves in and out of AtriCure's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -4.62 0.44 -2.40 10 -3.75 13 1.71 14 26 38 45
Net Cash From Operating Activities		 -7.84 -15 -8.94 -4.17 -16 -20 -14 -22 4.48 12 57
Net Cash From Continuing Operating Activities		 -7.84 -15 -8.94 -4.17 -16 -20 -14 -22 4.48 12 57
Net Income / (Loss) Continuing Operations		 -27 -33 -27 -21 -35 -48 50 -46 -30 -45 -11
Consolidated Net Income / (Loss)		 -27 -33 -27 -21 -35 -48 50 -46 -30 -45 -11
Depreciation Expense		 4.98 7.66 7.76 7.24 7.42 7.87 7.53 8.06 9.46 11 12
Amortization Expense		 1.94 1.99 1.66 1.66 1.40 3.43 6.15 5.64 6.47 8.10 8.92
Non-Cash Adjustments To Reconcile Net Income		 9.85 13 15 17 18 23 110 29 36 54 51
Changes in Operating Assets and Liabilities, net		 2.60 -4.11 -6.08 -8.66 -7.41 -5.65 -188 -18 -17 -16 -2.91
Net Cash From Investing Activities		 -11 -12 3.76 -85 -2.15 -156 24 44 22 30 -15
Net Cash From Continuing Investing Activities		 -11 -12 3.76 -85 -2.15 -156 24 44 22 30 -15
Purchase of Property, Plant & Equipment		 -13 -7.69 -6.38 -6.21 -12 -5.26 -9.75 -17 -12 -11 -9.05
Acquisitions		 -7.58 - 0.00 0.00 -17 - 0.00 0.00 -30 -12 -6.00
Sale of Property, Plant & Equipment		 0.00 0.00 0.00 0.01 0.04 - - 0.00 0.00 0.03 0.00
Sale and/or Maturity of Investments		 41 24 27 27 100 75 206 86 64 54 0.00
Other Investing Activities, net		 -11 - - 0.00 0.00 0.80 - - 0.00 0.00 0.50
Net Cash From Financing Activities		 14 28 2.76 100 14 189 -7.64 -7.06 -0.03 -3.60 1.18
Net Cash From Continuing Financing Activities		 14 28 2.76 100 14 189 -7.64 -7.06 -0.03 -3.60 1.18
Repayment of Debt		 -0.33 -0.56 -0.05 -2.89 -0.33 -0.70 -6.99 -0.90 -1.05 -64 5.05
Issuance of Debt		 0.00 25 0.00 17 20 0.00 5.00 0.00 0.00 61 0.00
Issuance of Common Equity		 1.54 1.62 2.11 85 2.66 192 4.18 4.23 5.26 5.06 5.92
Other Financing Activities, net		 13 1.64 0.70 0.43 -7.96 -2.19 -9.84 -10 -4.24 -5.93 -9.80
Effect of Exchange Rate Changes		 -0.24 -0.05 0.02 -0.18 -0.16 0.14 -0.37 -0.36 -0.06 -0.42 0.75
Cash Interest Paid		 0.23 1.51 2.00 3.87 3.72 4.37 4.22 4.27 6.38 5.95 5.26
Cash Income Taxes Paid		 0.02 0.03 0.04 0.07 0.26 0.22 0.19 0.19 0.40 0.62 1.29

Quarterly Cash Flow Statements for AtriCure

This table details how cash moves in and out of AtriCure's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 13 3.71 -19 41 24 -7.61 -23 18 30 20 -21
Net Cash From Operating Activities		 1.52 4.03 -21 7.38 20 5.84 -11 22 27 20 -4.00
Net Cash From Continuing Operating Activities		 1.52 4.03 -21 7.38 20 5.84 -11 22 27 20 -4.00
Net Income / (Loss) Continuing Operations		 -9.06 -9.79 -13 -8.01 -7.85 -16 -6.75 -6.19 -0.27 1.76 0.11
Consolidated Net Income / (Loss)		 -9.06 -9.79 -13 -8.01 -7.85 -16 -6.75 -6.19 -0.27 1.76 0.11
Depreciation Expense		 2.41 2.48 2.59 2.64 3.04 2.94 2.97 3.06 3.06 3.00 2.89
Amortization Expense		 1.99 1.99 2.15 1.95 2.01 2.00 2.23 2.23 2.23 2.23 2.49
Non-Cash Adjustments To Reconcile Net Income		 8.66 9.31 11 10 10 22 9.63 16 12 12 11
Changes in Operating Assets and Liabilities, net		 -2.48 0.04 -23 0.41 12 -5.93 -19 6.15 9.27 0.79 -21
Net Cash From Investing Activities		 12 -2.79 9.64 31 4.39 -15 -1.68 -7.66 -2.61 -2.60 -3.85
Net Cash From Continuing Investing Activities		 12 -2.79 9.64 31 4.39 -15 -1.68 -7.66 -2.61 -2.60 -3.85
Purchase of Property, Plant & Equipment		 -3.63 -2.79 -2.77 -2.38 -3.61 -2.69 -2.18 -2.66 -2.61 -1.60 -3.85
Other Investing Activities, net		 - - 0.00 - - - 0.50 - - - 0.00
Net Cash From Financing Activities		 0.13 2.36 -7.86 2.85 -0.33 1.74 -10 3.42 5.98 2.10 -13
Net Cash From Continuing Financing Activities		 0.13 2.36 -7.86 2.85 -0.33 1.74 -10 3.42 5.98 2.10 -13
Repayment of Debt		 -0.25 -0.26 -63 -0.41 -0.34 -0.28 -0.29 -0.29 5.95 -0.32 -1.97
Other Financing Activities, net		 0.38 -2.64 -6.15 3.26 0.00 -3.05 -10 3.71 0.04 -3.50 -11
Effect of Exchange Rate Changes		 -0.17 0.11 -0.11 -0.06 0.24 -0.50 0.20 0.54 -0.03 0.04 -0.16
Cash Interest Paid		 1.64 1.66 0.73 1.45 1.43 2.35 1.25 1.33 1.35 1.34 1.22
Cash Income Taxes Paid		 0.07 0.17 0.02 0.49 0.07 0.04 0.12 0.77 0.75 -0.34 0.09

Annual Balance Sheets for AtriCure

This table presents AtriCure's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 273 276 268 357 558 715 615 585 614 609 654
Total Current Assets		 75 86 82 175 143 307 196 215 266 268 323
Cash & Equivalents		 24 24 22 32 28 42 44 58 84 123 167
Accounts Receivable		 19 21 23 25 28 23 33 43 53 60 67
Inventories, net		 18 18 22 22 29 35 39 46 68 75 78
Prepaid Expenses		 - - 2.27 2.59 3.90 4.35 5.00 5.48 8.56 9.43 9.94
Plant, Property, & Equipment, net		 31 30 29 27 33 28 0.00 39 0.00 42 39
Total Noncurrent Assets		 167 161 157 155 382 380 419 331 348 300 293
Goodwill		 105 105 105 105 235 235 235 235 235 235 235
Intangible Assets		 54 52 51 49 130 128 43 39 64 56 48
Other Noncurrent Operating Assets		 0.32 0.32 0.68 0.50 4.74 2.35 37 5.77 49 8.60 9.73
Total Liabilities & Shareholders' Equity		 273 276 268 357 558 715 615 585 614 609 654
Total Liabilities		 86 108 107 107 311 302 132 129 148 148 162
Total Current Liabilities		 32 29 32 40 50 49 56 58 75 73 82
Accounts Payable		 13 11 12 9.66 15 13 19 20 27 25 25
Accrued Expenses		 18 16 19 26 33 28 36 33 45 46 53
Other Current Liabilities		 - - 0.56 4.72 2.22 8.42 1.76 - - 2.81 3.12
Total Noncurrent Liabilities		 55 79 75 67 261 253 75 70 73 75 81
Long-Term Debt		 0.00 24 24 36 60 53 60 57 61 62 62
Other Noncurrent Operating Liabilities		 41 42 38 19 189 189 15 4.32 13 13 19
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 187 168 161 249 247 412 484 457 466 461 492
Total Preferred & Common Equity		 187 168 161 249 247 412 484 457 466 461 492
Total Common Equity		 187 168 161 249 247 412 484 457 466 461 492
Common Stock		 353 368 387 497 530 742 765 787 824 864 905
Retained Earnings		 -166 -199 -226 -247 -282 -330 -280 -327 -357 -402 -413
Accumulated Other Comprehensive Income / (Loss)		 -0.61 -0.47 0.03 -0.20 -0.16 0.31 -0.95 -4.10 -0.99 -1.04 0.57

Quarterly Balance Sheets for AtriCure

This table presents AtriCure's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 583 594 600 592 597 615 592 609 635 644
Total Current Assets		 238 238 253 245 253 269 251 271 301 314
Cash & Equivalents		 77 67 81 65 106 130 100 118 148 146
Accounts Receivable		 46 48 52 55 56 55 63 66 63 71
Inventories, net		 49 55 62 72 74 77 75 76 79 81
Prepaid Expenses		 7.96 7.18 6.28 12 9.61 7.50 13 11 11 15
Plant, Property, & Equipment, net		 40 41 41 42 42 44 41 41 40 40
Total Noncurrent Assets		 305 316 306 304 302 302 299 297 295 291
Goodwill		 235 235 235 235 235 235 235 235 235 235
Intangible Assets		 39 67 66 62 60 58 54 52 50 46
Other Noncurrent Operating Assets		 6.23 5.89 5.69 7.46 7.23 9.11 9.77 9.88 9.86 10
Total Liabilities & Shareholders' Equity		 583 594 600 592 597 615 592 609 635 644
Total Liabilities		 128 132 137 135 135 150 137 144 159 152
Total Current Liabilities		 62 71 83 61 61 74 61 69 78 73
Accounts Payable		 24 24 25 29 27 32 25 26 25 31
Accrued Expenses		 28 32 37 30 32 40 33 40 49 40
Other Current Liabilities		 11 16 21 2.54 2.54 2.72 2.84 2.91 3.00 3.13
Total Noncurrent Liabilities		 66 60 55 74 74 76 76 76 81 79
Long-Term Debt		 52 47 42 62 62 62 62 62 62 61
Other Noncurrent Operating Liabilities		 14 13 13 12 12 14 14 14 19 18
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 455 462 463 456 462 465 455 464 477 492
Total Preferred & Common Equity		 455 462 463 456 462 465 455 464 477 492
Total Common Equity		 455 462 463 456 462 465 455 464 477 492
Common Stock		 791 803 812 827 841 851 863 878 891 905
Retained Earnings		 -333 -338 -347 -370 -378 -386 -409 -415 -415 -413
Accumulated Other Comprehensive Income / (Loss)		 -3.07 -2.61 -2.18 -0.70 -0.57 -0.15 -0.23 0.75 0.57 0.23

Annual Metrics And Ratios for AtriCure

This table displays calculated financial ratios and metrics derived from AtriCure's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 20.75% 19.54% 12.64% 15.40% 14.47% -10.52% 32.83% 20.43% 20.84% 16.55% 14.88%
EBITDA Growth		 -90.49% -9.54% 30.17% 45.50% -191.12% -34.75% 307.87% -143.07% 63.46% -94.95% 158.25%
EBIT Growth		 -69.54% -17.18% 21.70% 30.32% -92.27% -32.98% 223.91% -178.79% 38.17% -51.00% 78.27%
NOPAT Growth		 -63.33% -16.53% 19.78% 31.43% -93.39% -33.55% 277.63% -154.31% 37.47% -49.96% 76.39%
Net Income Growth		 -67.86% -22.51% 19.34% 21.40% -66.50% -36.83% 204.24% -192.56% 34.49% -46.85% 74.39%
EPS Growth		 -59.02% -8.25% 20.95% 25.30% -51.61% -21.28% 195.61% -193.58% 35.29% -43.94% 74.74%
Operating Cash Flow Growth		 63.69% -92.80% 40.84% 53.37% -279.07% -25.67% 30.65% -60.67% 120.25% 172.17% 369.80%
Free Cash Flow Firm Growth		 -270.02% 79.19% 12.00% -1.93% -253.63% 66.43% -86.00% -40.11% 15.73% 29.37% 119.74%
Invested Capital Growth		 147.48% 1.11% 2.03% 5.59% 29.85% -2.62% 46.55% 11.10% 10.24% 2.78% -3.43%
Revenue Q/Q Growth		 5.23% 3.53% 2.89% 3.51% 3.79% -1.71% 5.99% 4.69% 4.86% 3.96% 3.13%
EBITDA Q/Q Growth		 -29.98% 11.68% 27.31% -9.47% -100.14% -5.86% 8.69% 22.25% -48.38% -39.23% 317.73%
EBIT Q/Q Growth		 -24.58% 7.49% 19.47% -3.33% -60.68% -5.23% 9.46% 16.92% -21.57% -18.84% 66.74%
NOPAT Q/Q Growth		 -28.04% 8.61% 18.21% -2.83% -62.34% -5.18% 10.11% 16.39% -20.46% -17.14% 64.30%
Net Income Q/Q Growth		 -25.74% 6.42% 18.35% -4.19% -56.22% -5.40% 10.62% 17.08% -22.64% -14.85% 60.21%
EPS Q/Q Growth		 -25.97% 9.48% 18.63% 0.00% -59.32% 1.72% 13.54% 15.00% -20.00% -14.46% 60.66%
Operating Cash Flow Q/Q Growth		 -35.79% 24.25% 7.90% -14.97% -39.96% 27.36% -36.07% -1.17% 796.80% 17.37% 32.89%
Free Cash Flow Firm Q/Q Growth		 -659.43% 80.63% -3.25% 13.49% -10.57% 14.18% 8.93% -122.20% 85.78% 19.74% 157.12%
Invested Capital Q/Q Growth		 137.56% -2.55% 0.22% -1.86% -2.19% -4.67% -3.10% 0.00% 5.39% 1.61% -1.06%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 71.58% 71.63% 72.21% 72.97% 73.80% 72.29% 75.04% 74.44% 75.23% 74.69% 74.98%
EBITDA Margin		 -15.54% -14.24% -8.83% -4.17% -10.60% -15.96% 24.98% -8.93% -2.70% -4.52% 2.29%
Operating Margin		 -20.59% -20.07% -14.30% -8.49% -14.35% -21.42% 20.12% -12.92% -6.68% -8.60% -1.77%
EBIT Margin		 -20.87% -20.45% -14.22% -8.59% -14.42% -21.43% 19.99% -13.08% -6.69% -8.67% -1.64%
Profit (Net Income) Margin		 -20.97% -21.49% -15.39% -10.48% -15.25% -23.32% 18.30% -14.06% -7.62% -9.61% -2.14%
Tax Burden Percent		 100.13% 100.12% 100.05% 101.08% 100.57% 100.24% 99.63% 100.58% 101.98% 102.34% 112.64%
Interest Burden Percent		 100.38% 104.96% 108.20% 120.80% 105.15% 108.55% 91.88% 106.93% 111.73% 108.27% 115.96%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.37% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -16.80% -13.67% -10.80% -7.13% -11.68% -13.99% 20.43% -8.84% -5.00% -7.05% -1.68%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.81% 50.02% 318.92% 17.51% 12.40% 1.85% 23.11% 3.69% 8.42% 18.20% 4.13%
Return on Net Nonoperating Assets (RNNOA)		 -0.25% -5.10% -5.52% -3.17% -2.49% -0.61% -9.22% -1.04% -1.60% -2.60% -0.72%
Return on Equity (ROE)		 -17.05% -18.78% -16.32% -10.30% -14.17% -14.60% 11.20% -9.88% -6.60% -9.64% -2.40%
Cash Return on Invested Capital (CROIC)		 -101.69% -14.78% -12.80% -12.57% -37.65% -11.34% -17.33% -19.35% -14.74% -9.79% 1.81%
Operating Return on Assets (OROA)		 -12.55% -11.55% -9.13% -5.54% -7.28% -6.96% 8.25% -7.20% -4.45% -6.60% -1.39%
Return on Assets (ROA)		 -12.61% -12.13% -9.88% -6.77% -7.70% -7.57% 7.55% -7.74% -5.08% -7.31% -1.81%
Return on Common Equity (ROCE)		 -17.05% -18.78% -16.32% -10.30% -14.17% -14.60% 11.20% -9.88% -6.60% -9.64% -2.40%
Return on Equity Simple (ROE_SIMPLE)		 -14.58% -19.79% -16.69% -8.48% -14.23% -11.68% 10.38% -10.17% -6.53% -9.70% 0.00%
Net Operating Profit after Tax (NOPAT)		 -19 -22 -17 -12 -23 -31 55 -30 -19 -28 -6.61
NOPAT Margin		 -14.41% -14.05% -10.01% -5.95% -10.05% -14.99% 20.05% -9.04% -4.68% -6.02% -1.24%
Net Nonoperating Expense Percent (NNEP)		 -17.62% -63.69% -329.71% -24.64% -24.08% -15.84% -2.68% -12.53% -13.41% -25.25% -5.81%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -5.65% -3.53% -5.33% -1.19%
Cost of Revenue to Revenue		 28.42% 28.37% 27.79% 27.03% 26.20% 27.71% 24.96% 25.56% 24.77% 25.31% 25.02%
SG&A Expenses to Revenue		 72.33% 68.61% 66.96% 64.24% 72.42% 73.03% 74.60% 70.00% 63.40% 62.62% 58.19%
R&D to Revenue		 19.84% 23.10% 19.54% 17.22% 17.86% 20.85% 17.68% 17.35% 18.51% 20.67% 18.56%
Operating Expenses to Revenue		 92.17% 91.70% 86.51% 81.46% 88.15% 93.71% 54.92% 87.36% 81.92% 83.29% 76.75%
Earnings before Interest and Taxes (EBIT)		 -27 -32 -25 -17 -33 -44 55 -43 -27 -40 -8.76
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -20 -22 -15 -8.40 -24 -33 69 -30 -11 -21 12
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.87 3.86 3.90 4.73 5.20 6.08 6.60 4.51 3.63 3.23 4.00
Price to Tangible Book Value (P/TBV)		 26.14 58.85 122.22 12.43 0.00 50.72 15.50 11.28 10.10 8.78 9.40
Price to Revenue (P/Rev)		 5.57 4.19 3.60 5.85 5.57 12.14 11.64 6.24 4.24 3.20 3.68
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 63.62 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.57% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 4.38 4.01 3.86 6.38 5.63 10.59 9.47 5.51 4.13 3.55 4.82
Enterprise Value to Revenue (EV/Rev)		 5.35 4.14 3.61 5.47 5.47 11.20 11.05 5.93 4.05 3.08 3.48
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 44.22 0.00 0.00 0.00 152.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 55.25 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 55.09 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 360.70 117.33 32.46
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 261.11
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.08 0.23 0.23 0.19 0.29 0.16 0.12 0.16 0.14 0.14 0.13
Long-Term Debt to Equity		 0.07 0.22 0.23 0.19 0.29 0.16 0.12 0.14 0.13 0.13 0.13
Financial Leverage		 -0.30 -0.10 -0.02 -0.18 -0.20 -0.33 -0.40 -0.28 -0.19 -0.14 -0.17
Leverage Ratio		 1.35 1.55 1.65 1.52 1.84 1.93 1.48 1.28 1.30 1.32 1.33
Compound Leverage Factor		 1.36 1.62 1.79 1.84 1.94 2.09 1.36 1.37 1.45 1.43 1.54
Debt to Total Capital		 7.05% 18.76% 18.61% 16.07% 22.40% 13.51% 10.99% 13.53% 11.93% 12.30% 11.17%
Short-Term Debt to Total Capital		 0.22% 0.81% 0.00% 0.00% 0.00% 0.00% 0.00% 1.04% 0.48% 0.53% 0.00%
Long-Term Debt to Total Capital		 6.83% 17.94% 18.61% 16.07% 22.40% 13.51% 10.99% 12.49% 11.45% 11.77% 11.17%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 92.95% 81.24% 81.39% 83.93% 77.60% 86.49% 89.01% 86.47% 88.07% 87.70% 88.83%
Debt to EBITDA		 -0.70 -1.76 -2.39 -5.68 -2.92 -1.95 0.87 -2.42 -5.85 -3.08 5.05
Net Debt to EBITDA		 1.40 0.37 -0.16 9.12 0.94 5.89 -2.39 3.43 6.88 2.76 -8.62
Long-Term Debt to EBITDA		 -0.68 -1.68 -2.39 -5.68 -2.92 -1.95 0.87 -2.24 -5.62 -2.94 5.05
Debt to NOPAT		 -0.76 -1.78 -2.11 -3.98 -3.08 -2.08 1.09 -2.39 -3.38 -2.31 -9.36
Net Debt to NOPAT		 1.50 0.37 -0.14 6.39 0.99 6.27 -2.98 3.39 3.97 2.07 15.96
Long-Term Debt to NOPAT		 -0.73 -1.71 -2.11 -3.98 -3.08 -2.08 1.09 -2.21 -3.24 -2.21 -9.36
Altman Z-Score		 4.51 3.04 2.93 6.48 2.19 4.85 14.94 9.47 6.94 6.03 7.60
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.37 2.97 2.58 4.34 2.87 6.24 3.47 3.69 3.57 3.65 3.96
Quick Ratio		 1.71 2.26 1.80 3.72 2.20 5.44 2.69 2.81 2.55 2.49 2.87
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -113 -24 -21 -21 -75 -25 -47 -65 -55 -39 7.13
Operating Cash Flow to CapEx		 -58.33% -196.63% -140.10% -67.22% -130.21% -377.81% -141.29% -131.16% 37.37% 106.73% 633.52%
Free Cash Flow to Firm to Interest Expense		 -387.66 -13.08 -9.16 -4.59 -18.18 -5.14 -9.49 -13.11 -7.96 -5.01 1.21
Operating Cash Flow to Interest Expense		 -26.86 -8.39 -3.95 -0.91 -3.85 -4.07 -2.80 -4.44 0.65 1.57 9.75
Operating Cash Flow Less CapEx to Interest Expense		 -72.90 -12.66 -6.77 -2.25 -6.80 -5.14 -4.79 -7.83 -1.09 0.10 8.21
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.60 0.56 0.64 0.65 0.50 0.32 0.41 0.55 0.67 0.76 0.85
Accounts Receivable Turnover		 7.02 7.66 7.91 8.35 8.67 8.07 9.77 8.73 8.39 8.25 8.42
Inventory Turnover		 2.31 2.49 2.42 2.43 2.33 1.78 1.85 1.99 1.74 1.64 1.74
Fixed Asset Turnover		 6.06 5.06 5.95 7.22 7.73 6.78 0.00 0.00 0.00 0.00 13.23
Accounts Payable Turnover		 3.62 3.76 4.20 4.94 4.92 4.13 4.37 4.39 4.19 4.50 5.31
Days Sales Outstanding (DSO)		 51.99 47.66 46.15 43.70 42.10 45.24 37.37 41.82 43.51 44.26 43.36
Days Inventory Outstanding (DIO)		 157.94 146.47 150.77 150.44 156.62 205.52 197.22 183.49 210.10 221.93 209.90
Days Payable Outstanding (DPO)		 100.78 97.11 86.84 73.96 74.26 88.29 83.52 83.20 87.22 81.17 68.69
Cash Conversion Cycle (CCC)		 109.15 97.01 110.07 120.18 124.46 162.46 151.07 142.11 166.40 185.02 184.56
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 159 160 164 173 224 218 320 356 392 403 386
Invested Capital Turnover		 1.17 0.97 1.08 1.20 1.16 0.93 1.02 0.98 1.07 1.17 1.36
Increase / (Decrease) in Invested Capital		 94 1.77 3.25 9.15 52 -5.87 102 36 36 11 -14
Enterprise Value (EV)		 695 642 631 1,102 1,263 2,312 3,030 1,959 1,617 1,432 1,861
Market Capitalization		 723 651 629 1,179 1,286 2,506 3,194 2,060 1,692 1,490 1,967
Book Value per Share		 $5.79 $5.07 $4.68 $6.47 $6.25 $9.16 $10.53 $9.99 $9.84 $9.46 $9.89
Tangible Book Value per Share		 $0.86 $0.33 $0.15 $2.46 ($2.97) $1.10 $4.48 $3.99 $3.53 $3.48 $4.21
Total Capital		 201 207 198 297 319 477 543 528 529 526 554
Total Debt		 14 39 37 48 71 64 60 71 63 65 62
Total Long-Term Debt		 14 37 37 48 71 64 60 66 61 62 62
Net Debt		 -28 -8.12 2.41 -77 -23 -194 -164 -101 -74 -58 -106
Capital Expenditures (CapEx)		 13 7.69 6.38 6.21 12 5.26 9.75 17 12 11 9.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 9.04 15 16 10 11 13 21 41 57 74 74
Debt-free Net Working Capital (DFNWC)		 44 59 50 134 93 258 140 162 194 197 241
Net Working Capital (NWC)		 43 57 50 134 93 258 140 157 192 194 241
Net Nonoperating Expense (NNE)		 8.51 12 9.41 9.15 12 17 4.80 17 12 17 4.84
Net Nonoperating Obligations (NNO)		 -28 -8.12 2.41 -77 -23 -194 -164 -101 -74 -58 -106
Total Depreciation and Amortization (D&A)		 6.92 9.64 9.42 8.91 8.82 11 14 14 16 19 21
Debt-free, Cash-free Net Working Capital to Revenue		 6.96% 9.39% 9.10% 4.99% 4.96% 6.48% 7.49% 12.46% 14.26% 16.01% 13.76%
Debt-free Net Working Capital to Revenue		 33.61% 37.77% 28.82% 66.69% 40.40% 124.73% 50.90% 49.12% 48.64% 42.38% 45.09%
Net Working Capital to Revenue		 33.27% 36.68% 28.82% 66.69% 40.40% 124.73% 50.90% 47.47% 48.01% 41.78% 45.09%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.97) ($1.05) ($0.83) ($0.62) ($0.94) ($1.14) $1.11 ($1.02) ($0.66) ($0.95) ($0.24)
Adjusted Weighted Average Basic Shares Outstanding		 32.27M 33.34M 34.56M 38.61M 40.05M 45.57M 45.07M 45.74M 46.31M 46.97M 47.75M
Adjusted Diluted Earnings per Share		 ($0.97) ($1.05) ($0.83) ($0.62) ($0.94) ($1.14) $1.09 ($1.02) ($0.66) ($0.95) ($0.24)
Adjusted Weighted Average Diluted Shares Outstanding		 32.27M 33.34M 34.56M 38.61M 40.05M 45.57M 46.04M 45.74M 46.31M 46.97M 47.75M
Adjusted Basic & Diluted Earnings per Share		 ($0.97) ($1.05) ($0.83) ($0.62) ($0.94) ($1.14) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 28.06M 31.61M 32.39M 34.09M 37.59M 42.13M 46.03M 93.14M 95.18M 48.88M 49.81M
Normalized Net Operating Profit after Tax (NOPAT)		 -19 -22 -17 -12 -27 -31 -47 -30 -19 -28 -6.61
Normalized NOPAT Margin		 -14.41% -14.05% -10.01% -5.95% -11.54% -15.11% -17.18% -9.04% -4.68% -6.02% -1.24%
Pre Tax Income Margin		 -20.94% -21.47% -15.38% -10.37% -15.16% -23.26% 18.37% -13.98% -7.48% -9.39% -1.90%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -92.72 -17.61 -10.97 -3.76 -8.10 -9.06 11.15 -8.67 -3.86 -5.19 -1.49
NOPAT to Interest Expense		 -64.05 -12.10 -7.72 -2.60 -5.64 -6.34 11.18 -5.99 -2.70 -3.61 -1.13
EBIT Less CapEx to Interest Expense		 -138.76 -21.88 -13.79 -5.10 -11.05 -10.14 9.17 -12.05 -5.59 -6.66 -3.03
NOPAT Less CapEx to Interest Expense		 -110.10 -16.37 -10.54 -3.95 -8.59 -7.42 9.20 -9.38 -4.43 -5.08 -2.66
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.24% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for AtriCure

This table displays calculated financial ratios and metrics derived from AtriCure's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 49,809,901.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 49,809,901.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 0.00
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 18.07% 21.03% 16.43% 15.21% 17.93% 16.64% 13.57% 17.09% 15.84% 13.05% 14.26%
EBITDA Growth		 52.31% -523.99% -160.57% -479.55% 44.11% -141.46% 85.15% 96.47% 362.57% 176.75% 730.86%
EBIT Growth		 27.69% -120.89% -95.12% -67.33% 12.34% -73.87% 44.23% 24.65% 103.04% 116.83% 107.97%
NOPAT Growth		 24.56% -109.57% -88.81% -72.97% 8.46% -67.55% 45.46% 13.62% 102.81% 118.23% 103.46%
Net Income Growth		 26.21% -134.75% -104.90% -56.47% 13.27% -59.04% 49.15% 22.70% 96.60% 111.28% 101.60%
EPS Growth		 25.93% -110.00% -100.00% -54.55% 15.00% -57.14% 50.00% 23.53% 94.12% 112.12% 100.00%
Operating Cash Flow Growth		 185.31% 8,660.87% -415.22% 145.10% 1,214.32% 44.81% 47.54% 192.91% 33.55% 243.16% 63.76%
Free Cash Flow Firm Growth		 -216.99% -10.62% -6,331.09% -17.16% 92.12% 50.40% 88.53% 92.61% 120.80% 185.36% 219.53%
Invested Capital Growth		 0.00% 10.24% 19.36% 9.36% 6.61% 2.78% 1.06% -0.33% -1.52% -3.43% -2.42%
Revenue Q/Q Growth		 -2.60% 8.40% 2.17% 6.81% -0.31% 7.22% -0.53% 10.13% -1.37% 4.64% 0.53%
EBITDA Q/Q Growth		 -752.73% -11.59% -49.61% 59.29% 17.76% -382.12% 90.80% 90.32% 6,217.78% 40.92% -24.38%
EBIT Q/Q Growth		 -91.02% -6.23% -27.02% 35.09% -0.07% -110.71% 59.26% 12.29% 104.03% 1,067.28% -80.69%
NOPAT Q/Q Growth		 -95.20% -7.16% -25.95% 34.34% -3.31% -96.12% 59.00% -4.00% 103.36% 1,172.99% -92.22%
Net Income Q/Q Growth		 -76.92% -8.11% -35.55% 39.65% 1.94% -98.24% 56.66% 8.26% 95.69% 757.68% -93.85%
EPS Q/Q Growth		 -81.82% -5.00% -33.33% 39.29% 0.00% -94.12% 57.58% 7.14% 92.31% 500.00% -100.00%
Operating Cash Flow Q/Q Growth		 -49.45% 164.78% -621.49% 135.12% 171.06% -70.83% -288.93% 296.05% 23.59% -25.04% -119.95%
Free Cash Flow Firm Q/Q Growth		 -1,003.26% 88.75% -86.44% 46.17% 25.78% 29.19% 59.45% 65.31% 308.80% 151.95% -34.49%
Invested Capital Q/Q Growth		 -0.77% 5.39% 5.84% -0.56% -3.26% 1.61% 3.40% -1.93% -4.42% -1.06% 5.22%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 75.15% 74.91% 74.66% 74.69% 74.88% 74.53% 74.93% 74.54% 75.47% 74.97% 77.39%
EBITDA Margin		 -3.82% -3.93% -5.75% -2.19% -1.81% -8.14% -0.75% -0.07% 4.10% 5.52% 4.15%
Operating Margin		 -8.23% -8.14% -10.03% -6.17% -6.39% -11.69% -4.82% -4.55% 0.15% 1.77% 0.37%
EBIT Margin		 -8.29% -8.13% -10.10% -6.14% -6.16% -12.11% -4.96% -3.95% 0.16% 1.80% 0.35%
Profit (Net Income) Margin		 -9.21% -9.19% -12.19% -6.89% -6.78% -12.53% -5.46% -4.55% -0.20% 1.25% 0.08%
Tax Burden Percent		 100.52% 103.96% 101.40% 103.26% 104.28% 101.74% 103.67% 104.40% 310.47% 74.41% 27.41%
Interest Burden Percent		 110.51% 108.74% 118.97% 108.61% 105.40% 101.64% 106.10% 110.20% -39.63% 93.17% 80.57%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 25.59% 72.59%
Return on Invested Capital (ROIC)		 -11.79% -6.08% -7.68% -4.73% -5.21% -9.58% -3.91% -3.89% 0.14% 1.79% 0.14%
ROIC Less NNEP Spread (ROIC-NNEP)		 -4.33% -1.84% -0.36% -0.45% -1.86% -1.40% 2.38% -0.46% 0.68% 1.91% 0.20%
Return on Net Nonoperating Assets (RNNOA)		 0.85% 0.35% 0.06% 0.07% 0.32% 0.20% -0.21% 0.05% -0.11% -0.33% -0.03%
Return on Equity (ROE)		 -10.94% -5.73% -7.62% -4.66% -4.89% -9.38% -4.12% -3.84% 0.03% 1.46% 0.11%
Cash Return on Invested Capital (CROIC)		 -208.34% -14.74% -23.53% -15.16% -12.62% -9.79% -6.98% -5.49% -3.17% 1.81% 1.94%
Operating Return on Assets (OROA)		 -5.26% -5.41% -7.13% -4.43% -4.54% -9.22% -4.03% -3.28% 0.13% 1.53% 0.31%
Return on Assets (ROA)		 -5.84% -6.12% -8.60% -4.97% -4.99% -9.53% -4.43% -3.77% -0.16% 1.06% 0.07%
Return on Common Equity (ROCE)		 -10.94% -5.73% -7.62% -4.66% -4.89% -9.38% -4.12% -3.84% 0.03% 1.46% 0.11%
Return on Equity Simple (ROE_SIMPLE)		 -5.36% 0.00% -8.16% -8.68% -8.37% 0.00% -8.40% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -5.66 -6.07 -7.64 -5.02 -5.18 -10 -4.17 -4.33 0.15 1.85 0.14
NOPAT Margin		 -5.76% -5.70% -7.02% -4.32% -4.47% -8.18% -3.37% -3.18% 0.11% 1.32% 0.10%
Net Nonoperating Expense Percent (NNEP)		 -7.47% -4.25% -7.33% -4.28% -3.35% -8.17% -6.28% -3.43% -0.53% -0.12% -0.06%
Return On Investment Capital (ROIC_SIMPLE)		 - -1.15% - - - -1.93% -0.81% -0.82% 0.03% 0.33% 0.03%
Cost of Revenue to Revenue		 24.85% 25.09% 25.34% 25.31% 25.12% 25.47% 25.07% 25.46% 24.53% 25.03% 22.61%
SG&A Expenses to Revenue		 62.68% 63.53% 66.46% 63.30% 63.19% 58.08% 61.52% 57.58% 58.27% 55.76% 59.86%
R&D to Revenue		 20.71% 19.52% 18.23% 17.56% 18.08% 28.13% 18.22% 21.51% 17.05% 17.44% 17.16%
Operating Expenses to Revenue		 83.38% 83.05% 84.69% 80.86% 81.27% 86.21% 79.75% 79.09% 75.31% 73.20% 77.02%
Earnings before Interest and Taxes (EBIT)		 -8.15 -8.66 -11 -7.14 -7.15 -15 -6.13 -5.38 0.22 2.53 0.49
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.75 -4.19 -6.26 -2.55 -2.10 -10 -0.93 -0.09 5.51 7.76 5.87
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.48 3.63 3.16 2.38 2.94 3.23 3.47 3.49 3.68 4.00 2.89
Price to Tangible Book Value (P/TBV)		 12.77 10.10 9.04 6.59 7.94 8.78 9.53 9.14 9.14 9.40 6.73
Price to Revenue (P/Rev)		 5.45 4.24 3.48 2.56 3.05 3.20 3.28 3.24 3.38 3.68 2.57
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 5.33 4.13 3.39 2.56 3.27 3.55 3.69 3.83 4.27 4.82 3.29
Enterprise Value to Revenue (EV/Rev)		 5.21 4.05 3.37 2.44 2.90 3.08 3.21 3.13 3.21 3.48 2.42
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 152.00 70.16
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 3,966.13 360.70 0.00 0.00 124.74 117.33 69.34 42.99 38.62 32.46 20.76
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 261.11 167.11
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.09 0.14 0.14 0.13 0.13 0.14 0.14 0.13 0.13 0.13 0.12
Long-Term Debt to Equity		 0.09 0.13 0.14 0.13 0.13 0.13 0.14 0.13 0.13 0.13 0.12
Financial Leverage		 -0.20 -0.19 -0.17 -0.15 -0.17 -0.14 -0.09 -0.12 -0.16 -0.17 -0.13
Leverage Ratio		 1.30 1.30 1.29 1.29 1.31 1.32 1.30 1.30 1.33 1.33 1.31
Compound Leverage Factor		 1.43 1.41 1.53 1.40 1.38 1.34 1.38 1.43 -0.53 1.24 1.05
Debt to Total Capital		 8.35% 11.93% 11.94% 11.81% 11.74% 12.30% 11.98% 11.75% 11.49% 11.17% 11.04%
Short-Term Debt to Total Capital		 0.00% 0.48% 0.00% 0.00% 0.00% 0.53% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 8.35% 11.45% 11.94% 11.81% 11.74% 11.77% 11.98% 11.75% 11.49% 11.17% 11.04%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 91.65% 88.07% 88.06% 88.19% 88.26% 87.70% 88.02% 88.25% 88.51% 88.83% 88.96%
Debt to EBITDA		 -5.80 -5.85 -4.22 -3.69 -4.10 -3.08 -3.94 -4.68 -11.00 5.05 3.20
Net Debt to EBITDA		 12.50 6.88 3.01 3.11 4.54 2.76 2.42 4.23 15.29 -8.62 -4.47
Long-Term Debt to EBITDA		 -5.80 -5.62 -4.22 -3.69 -4.10 -2.94 -3.94 -4.68 -11.00 5.05 3.20
Debt to NOPAT		 -2.72 -3.38 -2.78 -2.54 -2.59 -2.31 -2.52 -2.59 -3.34 -9.36 -29.37
Net Debt to NOPAT		 5.86 3.97 1.98 2.14 2.86 2.07 1.55 2.34 4.64 15.96 41.01
Long-Term Debt to NOPAT		 -2.72 -3.24 -2.78 -2.54 -2.59 -2.21 -2.52 -2.59 -3.34 -9.36 -29.37
Altman Z-Score		 9.17 7.03 6.53 5.07 5.65 6.17 7.10 6.98 6.94 7.66 6.01
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.06 3.57 4.00 4.13 3.62 3.65 4.11 3.94 3.87 3.96 4.29
Quick Ratio		 2.24 2.55 2.63 2.77 2.49 2.49 2.67 2.67 2.71 2.87 2.97
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -378 -42 -74 -40 -30 -21 -8.55 -2.96 6.19 16 10
Operating Cash Flow to CapEx		 41.93% 144.65% -757.61% 309.56% 554.43% 216.71% -505.55% 812.06% 1,025.57% 1,250.12% -103.74%
Free Cash Flow to Firm to Interest Expense		 -213.11 -23.63 -24.51 -24.88 -17.85 -14.52 -6.04 -1.99 4.22 10.37 7.62
Operating Cash Flow to Interest Expense		 0.86 2.24 -6.92 4.58 12.00 4.02 -7.79 14.51 18.20 13.32 -2.98
Operating Cash Flow Less CapEx to Interest Expense		 -1.19 0.69 -7.83 3.10 9.84 2.17 -9.33 12.72 16.42 12.25 -5.86
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.63 0.67 0.71 0.72 0.74 0.76 0.81 0.83 0.83 0.85 0.89
Accounts Receivable Turnover		 7.39 8.39 8.21 8.27 8.41 8.25 8.09 8.22 8.79 8.42 8.20
Inventory Turnover		 1.54 1.74 1.70 1.68 1.63 1.64 1.65 1.69 1.68 1.74 1.73
Fixed Asset Turnover		 9.20 0.00 10.16 10.40 10.54 0.00 11.53 12.07 12.48 13.23 13.64
Accounts Payable Turnover		 3.87 4.19 3.90 4.29 4.01 4.50 4.47 4.83 4.55 5.31 4.83
Days Sales Outstanding (DSO)		 49.40 43.51 44.45 44.11 43.40 44.26 45.10 44.38 41.51 43.36 44.50
Days Inventory Outstanding (DIO)		 237.65 210.10 214.92 217.78 223.88 221.93 221.15 216.53 217.88 209.90 211.44
Days Payable Outstanding (DPO)		 94.23 87.22 93.50 85.00 91.01 81.17 81.57 75.56 80.16 68.69 75.51
Cash Conversion Cycle (CCC)		 192.82 166.40 165.87 176.89 176.27 185.02 184.68 185.35 179.23 184.56 180.42
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 372 392 412 410 397 403 417 409 391 386 407
Invested Capital Turnover		 2.05 1.07 1.09 1.10 1.16 1.17 1.16 1.22 1.32 1.36 1.34
Increase / (Decrease) in Invested Capital		 372 36 67 35 25 11 4.38 -1.37 -6.04 -14 -10
Enterprise Value (EV)		 1,983 1,617 1,398 1,050 1,297 1,432 1,539 1,566 1,666 1,861 1,336
Market Capitalization		 2,074 1,692 1,442 1,102 1,365 1,490 1,577 1,622 1,752 1,967 1,421
Book Value per Share		 $9.77 $9.84 $9.77 $9.55 $9.55 $9.46 $9.30 $9.38 $9.59 $9.89 $9.87
Tangible Book Value per Share		 $3.43 $3.53 $3.41 $3.45 $3.53 $3.48 $3.39 $3.58 $3.85 $4.21 $4.24
Total Capital		 505 529 518 524 527 526 516 526 538 554 553
Total Debt		 42 63 62 62 62 65 62 62 62 62 61
Total Long-Term Debt		 42 61 62 62 62 62 62 62 62 62 61
Net Debt		 -91 -74 -44 -52 -68 -58 -38 -56 -86 -106 -85
Capital Expenditures (CapEx)		 3.63 2.79 2.77 2.38 3.61 2.69 2.18 2.66 2.61 1.60 3.85
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 37 57 78 78 65 74 90 85 75 74 94
Debt-free Net Working Capital (DFNWC)		 170 194 184 192 195 197 190 202 223 241 241
Net Working Capital (NWC)		 170 192 184 192 195 194 190 202 223 241 241
Net Nonoperating Expense (NNE)		 3.39 3.72 5.63 2.99 2.67 5.40 2.58 1.86 0.41 0.10 0.04
Net Nonoperating Obligations (NNO)		 -91 -74 -44 -52 -68 -58 -38 -56 -86 -106 -85
Total Depreciation and Amortization (D&A)		 4.40 4.47 4.74 4.59 5.05 4.95 5.20 5.29 5.29 5.23 5.38
Debt-free, Cash-free Net Working Capital to Revenue		 9.76% 14.26% 18.82% 18.05% 14.42% 16.01% 18.83% 16.93% 14.55% 13.76% 17.09%
Debt-free Net Working Capital to Revenue		 44.70% 48.64% 44.37% 44.57% 43.54% 42.38% 39.63% 40.49% 43.08% 45.09% 43.56%
Net Working Capital to Revenue		 44.70% 48.01% 44.37% 44.57% 43.54% 41.78% 39.63% 40.49% 43.08% 45.09% 43.56%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.20) ($0.21) ($0.28) ($0.17) ($0.17) ($0.33) ($0.14) ($0.13) ($0.01) $0.04 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 46.41M 46.31M 46.72M 46.91M 47.11M 46.97M 47.39M 47.72M 47.92M 47.75M 48.33M
Adjusted Diluted Earnings per Share		 ($0.20) ($0.21) ($0.28) ($0.17) ($0.17) ($0.33) ($0.14) ($0.13) ($0.01) $0.04 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 46.41M 46.31M 46.72M 46.91M 47.11M 46.97M 47.39M 47.72M 47.92M 47.75M 49.05M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 47.40M 95.18M 48.38M 48.70M 48.75M 48.88M 49.50M 49.70M 49.72M 49.81M 50.64M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.66 -6.07 -7.64 -5.02 -5.18 -10 -4.17 -4.33 0.15 1.85 0.37
Normalized NOPAT Margin		 -5.76% -5.70% -7.02% -4.32% -4.47% -8.18% -3.37% -3.18% 0.11% 1.32% 0.26%
Pre Tax Income Margin		 -9.16% -8.84% -12.02% -6.67% -6.50% -12.31% -5.26% -4.36% -0.06% 1.68% 0.28%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -4.60 -4.82 -3.62 -4.43 -4.29 -10.38 -4.33 -3.61 0.15 1.68 0.36
NOPAT to Interest Expense		 -3.20 -3.37 -2.51 -3.11 -3.11 -7.01 -2.94 -2.91 0.10 1.23 0.11
EBIT Less CapEx to Interest Expense		 -6.65 -6.37 -4.53 -5.91 -6.45 -12.23 -5.87 -5.40 -1.63 0.62 -2.51
NOPAT Less CapEx to Interest Expense		 -5.24 -4.92 -3.43 -4.59 -5.27 -8.86 -4.48 -4.70 -1.68 0.17 -2.77
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Here are the top factors from AtriCure's quarterly filings (last four years). The items are ordered with positives first, then neutral points, and finally the negative observations.

  • Q4 2025 revenue reached $140.5M with a gross margin around 75% (Gross Profit about $105.3M on $140.5M revenue), indicating solid core profitability on product sales.
  • Q4 2025 operating income turned positive at about $2.49M, reflecting a favorable shift in operating profitability compared with earlier 2025 quarters.
  • Q4 2025 net income from continuing operations was positive at roughly $1.76M, with basic and diluted EPS at $0.04, signaling a meaningful quarterly improvement in bottom-line performance.
  • Q4 2025 cash flow from continuing operating activities was about $20.0M, contributing to solid near-term liquidity.
  • Strong liquidity and balance-sheet anchors: cash and equivalents in the high hundreds of millions historically, total assets around $600M+, total equity near $476M, and modest long-term debt (roughly $61.9M), supporting financial flexibility.
  • Revenue shows an uneven but improving trend in 2025, climbing from about $123.6M in Q1 2025 to $140.5M in Q4 2025, suggesting improving demand through the year but not a straight, linear rise.
  • R&D expense remains sizable (roughly $22–$29M per quarter in 2025), indicating ongoing investment in product development and potential long-term growth drivers.
  • Selling, General & Administrative (SG&A) costs run high (roughly $72–$79M per quarter), which can constrain margins if revenue growth slows.
  • Net income has been negative for multiple quarters across 2023–2025, with only a partial rebound in Q4 2025, highlighting continued profitability challenges.
  • Even with recent improvements, quarterly profitability remains uneven, and several quarters in 2025 posted losses before the Q4 uplift, underscoring earnings volatility.
05/20/26 05:47 PM ETAI Generated. May Contain Errors.

AtriCure Financials - Frequently Asked Questions

According to the most recent income statement we have on file, AtriCure's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

AtriCure's net income appears to be on a downward trend, with a most recent value of -$11.45 million in 2025, falling from -$27.21 million in 2015. The previous period was -$44.70 million in 2024. See where experts think AtriCure is headed by visiting AtriCure's forecast page.

AtriCure's total operating income in 2025 was -$9.45 million, based on the following breakdown:
  • Total Gross Profit: $400.78 million
  • Total Operating Expenses: $410.23 million

Over the last 10 years, AtriCure's total revenue changed from $129.76 million in 2015 to $534.53 million in 2025, a change of 312.0%.

AtriCure's total liabilities were at $162.24 million at the end of 2025, a 9.4% increase from 2024, and a 87.8% increase since 2015.

In the past 10 years, AtriCure's cash and equivalents has ranged from $21.81 million in 2017 to $167.43 million in 2025, and is currently $167.43 million as of their latest financial filing in 2025.

Over the last 10 years, AtriCure's book value per share changed from 5.79 in 2015 to 9.89 in 2025, a change of 70.8%.


Related Companies

Financial statements for NASDAQ:ATRC last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...
Brownstone Research | Sponsoredtc pixel
No. You’re not imagining it…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Trump Is Eyeing the Biggest Monetary Shift Since Nixon
On August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...
Americas Gold Company | Sponsoredtc pixel
Are we ignoring the same signal Wall Street ignored in 1929?
In 1929, Irving Weiss spotted a systemic crisis hiding beneath record highs and shorted the market - turning $...
Weiss Ratings | Sponsoredtc pixel